ClinicalTrials.gg

Program

HBS-301

A development code. Also written as “HBS-301 tablet”, “Pitolisant delayed-release” and “HBS-201”.

Its studies are mostly in Cataplexy · Idiopathic Hypersomnia · Narcolepsy, led by Harmony Biosciences.

Furthest: phase 3, since Mar 21, 20264 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Harmony Biosciences42 open or runningphase 3since Mar 21, 2026Jun 30, 2025Oct 2027phase 3 · NCT07675135

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2025First study: phase 1 study in NarcolepsyFirst studyNCT07051252 · 46 enrolled · United States
  2. Mar 21, 2026Phase 3 study in Idiopathic HypersomniaPhase 3 reachedNCT07500090 · 248 planned · United States, Canada
  3. Jun 22, 2026Phase 3 study in CataplexyNCT07675135 · 258 planned · United States, Belgium, Canada and more
  4. Sep 30, 2026Phase 1 study in Healthy ParticipantsNCT07860736 · 12 enrolled · United States

Ahead

  1. Oct 2027Primary completion: phase 3 study in CataplexyNCT07675135
  2. Oct 2027Primary completion: phase 3 study in Idiopathic HypersomniaNCT07500090

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07860736Healthy Participants · United States1CompletedJun 28, 202612
NCT07675135Cataplexy · United States, Belgium, Canada and more3RecruitingOct 2027258
NCT07500090Idiopathic Hypersomnia · United States, Canada3RecruitingOct 2027248
NCT07051252Narcolepsy · United States1CompletedOct 13, 202546

How it is read

Names in the registry

  • “HBS-301”, 1 entry
  • “HBS-301 tablet”, 1 entry
  • “Pitolisant delayed-release”, 1 entry
  • “HBS-201”, 1 entry

Codes read as this program: HBS301, HBS201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.